DE60122767D1 - Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns - Google Patents

Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns

Info

Publication number
DE60122767D1
DE60122767D1 DE60122767T DE60122767T DE60122767D1 DE 60122767 D1 DE60122767 D1 DE 60122767D1 DE 60122767 T DE60122767 T DE 60122767T DE 60122767 T DE60122767 T DE 60122767T DE 60122767 D1 DE60122767 D1 DE 60122767D1
Authority
DE
Germany
Prior art keywords
treatment
compounds
cns disorders
lsulphonyl
indoly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60122767T
Other languages
English (en)
Other versions
DE60122767T2 (de
Inventor
Steven Mark Bromidge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0028708A external-priority patent/GB0028708D0/en
Priority claimed from GB0113517A external-priority patent/GB0113517D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of DE60122767D1 publication Critical patent/DE60122767D1/de
Publication of DE60122767T2 publication Critical patent/DE60122767T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE60122767T 2000-11-24 2001-11-16 Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns Expired - Fee Related DE60122767T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0028708A GB0028708D0 (en) 2000-11-24 2000-11-24 Novel compounds
GB0028708 2000-11-24
GB0113517A GB0113517D0 (en) 2001-06-04 2001-06-04 Novel Compounds
GB0113517 2001-06-04
PCT/EP2001/013411 WO2002041889A2 (en) 2000-11-24 2001-11-16 Indolsulfonyl compounds useful in the treatment of cns disorders

Publications (2)

Publication Number Publication Date
DE60122767D1 true DE60122767D1 (de) 2006-10-12
DE60122767T2 DE60122767T2 (de) 2007-09-13

Family

ID=26245327

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60122767T Expired - Fee Related DE60122767T2 (de) 2000-11-24 2001-11-16 Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns

Country Status (8)

Country Link
US (1) US20050176705A1 (de)
EP (1) EP1335722B1 (de)
JP (1) JP2004517072A (de)
AT (1) ATE337780T1 (de)
AU (1) AU2002220715A1 (de)
DE (1) DE60122767T2 (de)
ES (1) ES2271124T3 (de)
WO (1) WO2002041889A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003397A (es) 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.
BR0210411A (pt) 2001-06-15 2004-08-17 Hoffmann La Roche Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
ATE401072T1 (de) * 2002-02-12 2008-08-15 Organon Nv 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
CN1293053C (zh) * 2002-06-05 2007-01-03 弗·哈夫曼-拉罗切有限公司 作为5－ht6－受体调节剂用于治疗cns－病症的1－磺酰基－4－氨基烷氧基吲哚衍生物
DE60322551D1 (de) 2002-09-17 2008-09-11 Hoffmann La Roche 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren
RU2324693C2 (ru) * 2002-10-18 2008-05-20 Ф.Хоффманн-Ля Рош Аг 4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6
CN101544592B (zh) * 2002-11-28 2013-08-21 苏文生命科学有限公司 N-芳基磺酰-3-取代吲哚制备的替代方法
TWI289141B (en) * 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
BRPI0509759A (pt) 2004-04-13 2007-10-16 Warner Lambert Co moduladores de androgênio
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AU2007217040A1 (en) * 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
CA2655694C (en) 2006-07-03 2014-12-16 Biovitrum Ab (Publ) 1,4-substituted indoles useful for modulation of the 5-ht6 receptor
EP2121603A2 (de) * 2007-02-16 2009-11-25 Memory Pharmaceuticals Corporation 6'-substituierte indol- und indazol-derivate mit 5-ht6-rezeptoraffinität
JP2010521516A (ja) * 2007-03-21 2010-06-24 グラクソ グループ リミテッド 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用
JP2010528037A (ja) * 2007-05-24 2010-08-19 メモリー・ファーマシューティカルズ・コーポレイション ５−ｈｔ６受容体親和性を有する４’置換化合物
AU2008286760A1 (en) * 2007-08-15 2009-02-19 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-HT6 receptor affinity
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
US9974785B2 (en) 2014-07-08 2018-05-22 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
CN111362859B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111233737B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途
CN111362858B (zh) * 2020-03-16 2021-05-11 东莞市东阳光新药研发有限公司 芳杂环类衍生物的盐及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808581A (en) * 1986-03-17 1989-02-28 Glaxo Group Limited Imidazolyl- indolylpropanones as 5-HT3 receptor antagonists
GB8623819D0 (en) * 1986-10-03 1986-11-05 Glaxo Group Ltd Heterocyclic compounds
US4859662A (en) * 1986-11-28 1989-08-22 Glaxo Group Limited Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances
GB8720693D0 (en) * 1987-09-03 1987-10-07 Glaxo Group Ltd Chemical compounds
JPH0256485A (ja) * 1988-04-27 1990-02-26 Glaxo Group Ltd ラクタム誘導体
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
ZA902794B (en) * 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5965574A (en) * 1996-08-13 1999-10-12 Chen; Yuhpyng Liang Heteroaryl amines as novel acetylcholinesterase inhibitors
EP0773942A1 (de) * 1994-07-26 1997-05-21 Pfizer Inc. 4-indolderivate als serotonin agonisten und antagonisten
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6818639B2 (en) * 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
MXPA03003397A (es) * 2000-10-20 2004-06-30 Biovitrum Ab N1-(bencensulfonil)indoles sustituidos en las posiciones 2-, 3-, 4-, o 5 y su uso en terapia.

Also Published As

Publication number Publication date
ATE337780T1 (de) 2006-09-15
EP1335722A2 (de) 2003-08-20
US20050176705A1 (en) 2005-08-11
WO2002041889A2 (en) 2002-05-30
JP2004517072A (ja) 2004-06-10
DE60122767T2 (de) 2007-09-13
AU2002220715A1 (en) 2002-06-03
ES2271124T3 (es) 2007-04-16
WO2002041889A3 (en) 2003-04-10
EP1335722B1 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
GB0111186D0 (en) Novel compounds
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
BG66080B1 (bg) Заместени тиоацетамиди
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
GB0320320D0 (en) Novel compounds
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
UY26426A1 (es) Nuevos compuestos
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE266024T1 (de) Indolderivate die zur behandlung von störungen des cns benutzt werden können
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
DE60124791D1 (de) S-Methyl-Dihydro-Ziprasidone zur Behandlung von psychiatrischen Störungen.
DE50010972D1 (de) UBICHINON Qn ZUR BEHANDLUNG VON MIGRÄNESCHMERZEN
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BROMIDGE, STEVEN MARK, ESSEX CM 19 5AW, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee